Actualités et vidéos - GENMAB A/S GNMSF

Company Announcement COPENHAGEN , Denmark; November 16 , 20 2 1 – Genmab A/S ( Nasdaq: GM AB ) will increase its share capital by 17,862 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 250 shares at DKK 337.40, 1,825 shares at DKK 466.20, 1,250 shares at DKK 636.50, 87 shares at DKK...

November 10, 2021; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2021 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Genmab and Seagen Inc. (Seagen) accelerated Approval for TIVDAK™ (tisotumab vedotin- tftv ) for patients with recurrent or metastatic cervical cancer DARZALEX ® net sales as reported by Johnson & Johnson increased 49 % compared to the first nine months of 2020 to USD 4,378 million, resulting in royalty income of DKK 4,167...

Company Announcement Genmab improv es its 2021 financial guidance COPENHAGEN , Denmark; November 4 , 20 2 1 – Genmab A/S ( Nasdaq: GMAB ) announced today that it is improving its 2021 financial guidance published on August 11, 2021 . The improved guidance is driven primarily by increased royalty revenue related to the net sales of DARZALEX ® (daratumumab), both intravenous and subcutaneous formulations, and lower operating expense resulting from timing of investments for R&D activities and...

Media Release Copenhagen, Denmark, November 4 , 2021 Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody ® -CD3xCD20) in combination with other treatments in patients with B-cell non-Hodgkin lymphoma (NHL) Poster presentation highlighting preliminary data from clinical trial evaluating epcoritamab in patients with chronic lymphocytic leukemia (CLL) More than 20 abstracts evaluating Genmab owned and partnered programs accepted for presentation at ASH...

Media Release Copenhagen, Denmark, November 0 3 , 20 2 1 Genmab A/S ( Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will take part in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2021 . A webcast of the event will be available on Genmab’s website from November 18, 2021, 9:00 AM CET at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology company with a core purpose to...

Company Announcement Net sales of DARZALEX ® in the third quarter of 2021 totaled USD 1,580 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 19 , 20 21 – Genmab A/S ( Nasdaq : GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) formulation ( daratumumab and hyaluronidase- fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by...

Media Release Copenhagen, Denmark, October 15, 2021 Janssen- Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe for the treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor e xon 20 insertion mutations, after failure of platinum-based therapy Represents First CHMP opinion for a DuoBody ® product candidate Genmab A/S (Nasdaq: GMAB ) announced...

Company Announcement COPENHAGEN , Denmark; October 7 , 20 2 1 – Genmab A/S ( Nasdaq: GMAB ) announced today that at a board meeting the board decided to grant 18,689 restricted stock units and 21,537 warrants to employees of the company and three of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price...

Media Release Copenhagen, Denmark, October 1 , 2021 Mini-oral presentation highlighting data from first-in-human trial evaluating investigational bispecific antibody D uoBody ® -CD40×4-1BB (GEN1042) P oster presentation of clinical results from study evaluating investigational bispecific antibod y DuoBody ® - PD-L1×4-1BB (GEN1046) Additional poster presentations highlighting an investigational early-stage therapy in Genmab’s solid tumor product pipeline , new research and technolo gies...

Company Announcement COPENHAGEN , Denmark; September 21 , 20 2 1 – Genmab A/S ( Nasdaq: GMAB ) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,800 shares at DKK 337.40, 1,875 shares at DKK 939.50, 144 shares at DKK 1,145.00, and 150 shares at...

TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed o n Cervical Cancer C ells New Monotherapy Approved for Use in a Cancer with Limited Treatment Options COPENHAGEN , Denmark , and BOTHELL, Wash. ; September 20 , 20 2 1 – Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK TM (tisotumab vedotin-tftv), the first and only approved...

Media Release Tisotumab Vedotin in C ombination with C arboplatin S howed E ncouraging , D urable A nti- T umor A ctivity as F irst- L ine T reatment Tisotumab Vedotin i n C ombination with P embrolizumab S howed E ncouraging , D urable A nti- T umor A ctivity in P reviously T reated P atients COPENHAGEN , Denmark , and BOTHELL, Wash. ; Sept e mber 19, 2021 - Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today presented interim data from two cohorts of the Phase 1b/2 innovaTV 205...

Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial eval uating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL) published in The Lancet Results also presented during oral session at the 16 th Annual International Conference on Malignant Lymphoma (ICML) and as a poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association...

Media Release Copenhagen, Denmark, 2 7 August, 202 1 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley 1 9 th Annual Global Healthcare Conference at 8 : 00 A M EDT / 2 : 00 PM CEST on September 9 , 20 2 1 . A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at...

Company Announcement COPENHAGEN , Denmark; August 17 , 20 2 1 – Genmab A/S ( Nasdaq: GMAB ) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 200 shares at DKK 220.40, 1,100 shares at DKK 466.20, 200 shares at DKK 623.50, 750 shares at DKK...

August 1 1 , 20 2 1 ; Copenhagen, Denmark; Interim Report for the First Half of 20 2 1 Highlights The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application (BLA), for patients with recurrent or metastatic cervical cancer DARZALEX ® net sales increas ed 52% compared to the first half of 2020 to USD 2,798 million, resulting in royalty income of DKK 2,360 million Following a positive CHMP opinion, Janssen- Cilag International NV received European Marketing...

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 2 1 , 20 2 1 – Genmab A/S ( Nasdaq: GMAB ) announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners Limited Partnership has informed us that, as of J uly 1 6 , 202 1 , Artisan Partners Limited Partnership holds the voting rights to 3, 261,591 shares in Genmab A/S , which amounts to 4. 97 % of the share capital and voting rights in Genmab A/S. About Genmab Genmab...

Company Announcement Net sales of DARZALEX ® in the second quarter of 2021 totaled USD 1,433 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; July 21 , 20 21 – Genmab A/S ( Nasdaq : GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) formulation ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson &...

Company Announcement COPENHAGEN , Denmark; July 06, 20 2 1 – Genmab A/S ( Nasdaq: GMAB ) will increase its share capital by 47,974 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 660 shares at DKK 31.75, 550 shares at DKK 220.40, 9,487 shares at DKK 337.40, 125 shares at DKK 466.20,...

Company Announcement COPENHAGEN, Denmark; July 01, 2021 – Genmab A/S (Nasdaq: GMAB) announces that its share buy - back program has been completed on June 30, 2021. On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than June 30, 2021 and comprised up to 200,000 shares. The following...